Skip to main content
. 2021 Apr 15;2021:5544916. doi: 10.1155/2021/5544916

Table 1.

Sociodemographic and clinical characteristics of the study sample.

Variables Male n = 293
Mean (SD) or % (n)
Female n = 646
Mean (SD) or % (n)
Total n = 939
Mean (SD) or % (n)
Age in years 47 (11.5) 43 (10.2) 44 (10.7)
SBP (mmHg) 127.9 (17.9) 121.3 (17.8) 123.4 (18.1)
DBP (mmHg) 75.5 (11.7) 73.4 (10.1) 74.1 (10.7)
Weight (kg) 66.5 (13.1) 65.4 (13.5) 65.7 (13.4)
Height (meters) 1.70 (0.1) 1.59 (0.1) 1.62 (0.1)
BMI (kg/m2) 23.1 (4.2) 25.8 (5.1) 24.9 (4.9)

BMI categories
Underweight (BMI ≤18.4) 9.9 (29) 56.7 (38) 7.1 (67)
Normal (BMI 18.5–24.9) 61.8 (181) 40.4 (261) 47.1 (442)
Overweight/obese (BMI≥25) 28.3 (83) 53.7 (347) 45.8 (430)

Blood pressure categories
Normal BP (SBP < 130 and DBP < 85 mmHg) 59.7 (175) 70.6 (456) 67.2 (631)
Prehypertensive (SBP of 130–139 and/or DBP 85–89 mmHg) 15.0 (44) 13.5 (87) 131 (13.9)
Hypertensive (SBP ≥140 and/or DBP ≥ 90 mmHg) 25.3 (74) 15.9 (103) 18.9 (177)

ARV drugs
TDF/3TC/EFV 12 (35) 40.6 (262) 31.6 (297)
D4T/3TC/NVP 15.4 (45) 16.7 (108) 16.3 (153)
TDF/3TC/NVP 1.7 (5) 7.6 (49) 5.8 (54)
TDF/3TC/DTG 50.5 (148) 14.9 (96) 26 (244)
TDF or AZT/3TC/LPV/r or ATV/r 4.8 (14) 3.9 (25) 4.2 (39)
AZT/3TC/NVP 3.1 (9) 7.7 (50) 6.3 (59)
3TC/D4T/EFV 8.9 (26) 5.4 (35) 6.5 (61)
Others 3.8 (11) 3.2 (21) 3.4 (32)

ART regimen
NNRTIs and NRTIs 38.6 (113) 77.6 (501) 65.4 (614)
NRTIs and PIs 5.8 (17) 4.6 (30) 5.0 (47)
NRTIs and INSTIs 55.6 (163) 17.8 (115) 29.6 (278)

Duration of ARV therapy
<2 years 13.3 (39) 10.8 (70) 11.6 (109)
≥2 years 86.7 (254) 89.2 (576) 88.4 (830)

History of smoking
Yes 14.3 (42) 1.9 (12) 5.8(54)
No 85.7 (251) 98.1 (634) 94.2(885)

History of alcohol consumption
Yes 22.1 (59) 6.1 (39) 11.1 (95)
No 77.9 (208) 93.9 (550) 88.9 (758)

SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ARV: antiretroviral; ART: antiretroviral therapy; AZT: zidovudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; TDF: tenofovir disoproxil fumarate; DTG: dolutegravir; D4T: stavudine; LPV/r: lopinavir/ritonavir; ATV/r: atazanavir/ritonavir; NNRTIs: nonnucleoside reverse transcriptase inhibitors; NRTI: nucleoside and nucleotide reverse transcriptase inhibitors; INSTIs: integrase strand transfer inhibitor.